[Role of antiarrhythmics in the treatment of paroxysmal atrial fibrillation].
Atrial fibrillation is not a homogenous entity. Numerous parameters affect its cause, its continuation, and the arrest of an attack. The presence or absence of cardiopathy and left ventricular dysfunction play a major role via the electrophysiological and haemodynamic consequences and the repercussions on the state of the autonomic nervous system, and finally on the effect of anti-arrhythmics themselves. This shows the importance of taking into account all of these parameters together in order to adapt the therapeutic approach. Equally, this underlines the difficulty in interpreting clinical studies comparing pharmacological treatments when the populations treated are poorly defined or very heterogenous. Most often, one drug is not more or less effective than another, it is more or less suited to the patients treated. The frequency of recurrences of AF despite anti-arrhythmic treatment (on average 50% to 60% at one year) means that in paroxysmal AF the goal of anti-arrhythmic treatment is relatively modest: essentially reducing the frequency, duration and severity of AF attacks, allowing an improvement in the quality of life. The consequences in daily practice are clear: one must ensure good patient compliance and minimise the risks of treatment: side effects of and pro-arrhythmic effects of anti-arrhythmics.
Leenhardt
A
A
Service de cardiologie, hôpital Lariboisière, 2, rue Ambroise Paré, 75475 Paris.
Extramiana
F
F
Cauchemez
B
B
Denjoy
I
I
Maison-Blanche
P
P
Coumel
Ph
P
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D004594:Electrophysiology; D006439:Hemodynamics; D006801:Humans; D010349:Patient Compliance; D011788:Quality of Life; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index
D000889:Anti-Arrhythmia Agents
Place des antiarythmiques dans le traitement de la fibrillation auriculaire paroxystique.